Showing 4481-4490 of 6036 results for "".
- Omeros Receives $200 Million Milestone Payment from Raynerhttps://modernod.com/news/omeros-receives-200-million-milestone-payment-from-rayner/2481391/Omeros announced that Rayner has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021, pursuant to which Omeros sold its ophthalmology product Omidria to Rayner in December of 2021. Omeros received
- Nidek Launches Cube Alpha Ophthalmic Surgical Systemhttps://modernod.com/news/nidek-launches-cube-a-ophthalmic-surgical-system/2481390/Nidek has announced the launch of the Cube α ophthalmic surgical system, which is designed to incorporate new ultrasound technology to deliver more powerful and effective phacoemulsification. According to Nidek, the Cube α incorporates Gyro torsional technolog
- Viridian Appoints Scott Myers as President and Chief Executive Officerhttps://modernod.com/news/viridian-appoints-scott-myers-as-president-and-chief-executive-officer/2481388/Viridian Therapeutics has appointed Scott Myers as President and Chief Executive Officer, as well as a member of the Board of Directors, effective February 6, 2023. He succeeds Jonathan Violin, PhD, who has led Viridian since its inception in 2020. “Our progres
- Tracey Technologies Launches iTrace Prime Upgraded Software for iTrace Aberrometerhttps://modernod.com/news/tracey-technologies-launches-itrace-prime-upgraded-software-for-itrace-aberrometer/2481384/Tracey Technologies announced the release of iTrace Prime, an upgraded software for the iTrace Ray Tracing aberrometer and corneal topographer. This new software version (7.0) adds new features that improve the range of information able to be gathered from a single device, accordi
- Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-6-month-results-from-oasis-extension-study-with-suprachoroidal-cls-ax-in-wet-amd/2481380/Clearside Biomedical announced positive results from the extension study of its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) parti
- Nidek Launches the AL-Scan M Optical Biometerhttps://modernod.com/news/nidek-launches-the-al-scan-m-optical-biometer/2481376/Nidek has announced the launch of the AL-Scan M Optical Biometer and the MV-1 Myopia Viewer software. The AL-Scan M incorporates 3D auto tracking and auto shot functions, designed for easy operation and quick measurement similar to an auto refractometer. Nidek says the features&nbs
- VSP Vision Names New President of VSP Ventureshttps://modernod.com/news/kathleen-steele-named-president-of-vsp-ventures/2481370/VSP Vision announced that Kathleen Steele has been named president of VSP Ventures. In the role, Ms. Steele will lead the company’s business unit that provides care-focused choices for doctors of optometry looking for practice transition options. She will report to Kate Renwick-Es
- Johns Hopkins Researchers Explore Why Episodes of Low Blood Sugar Worsen Eye Disease in People with Diabeteshttps://modernod.com/news/johns-hopkins-researchers-explore-why-episodes-of-low-blood-sugar-worsen-eye-disease-in-people-with-diabetes/2481367/Researchers at Johns Hopkins Medicine say they have linked low blood sugar levels in people with diabetes with a molecular pathway that is turned on in oxygen-starved cells in the eye. The research, involving human and mouse eye cells and intact retinas grown in a low sugar (low glucose
- Three-Month Efficacy/Safety Data of SING IMT for AMD Publishedhttps://modernod.com/news/three-month-efficacysafety-data-of-sing-imt-for-amd-published/2481362/The first and largest single-surgeon case series to describe the short-term (3 months) safety and efficacy outcomes of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) in patients with severe to profound bilateral central vision impairment due to advanced A
- Harrow Completes Acquisition of US Rights to Five Branded Ophthalmic Drugshttps://modernod.com/news/harrow-closes-acquisition-of-us-rights-to-ilevro-nevanac-vigamox-maxidex-and-triesence-and-will-begin-receiving-net-profit-payments-for-acquired-products/2481361/Harrow announced the closing of its previously announced acquisition with Novartis of the exclusive US commercial rights to five branded ophthalmic products: Ilevro, Nevanac, Vigamox, Maxidex, and Triesence. In December, Harrow announced it had